senicapoc and Anemia, Sickle Cell
senicapoc has been researched along with Anemia, Sickle Cell in 16 studies
Research
Studies (16)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (50.00) | 29.6817 |
2010's | 7 (43.75) | 24.3611 |
2020's | 1 (6.25) | 2.80 |
Authors
Authors | Studies |
---|---|
Beuzard, Y; Brugnara, C; Corrocher, R; De Franceschi, L; McNaughton-Smith, GA; Stocker, JW | 1 |
Arrington, S; Burns, JF; Creech, C; de Franceschi, L; McNaughton-Smith, GA; Rigdon, GC; Shelton, T; Stocker, JW | 1 |
Ataga, KI; Brugnara, C; Staffa, SJ; Stocker, JW | 1 |
Ballas, SK; Nagalla, S | 4 |
Ataga, KI; Stocker, J | 1 |
Ataga, KI; Ballas, SK; Bigelow, C; Galacteros, F; Hull, JH; James, LS; Kutlar, A; Reid, M; Smith, WR; Stocker, JW; Yasin, Z | 1 |
Kato, GJ; Mendelsohn, L; Minniti, CP; Remaley, AT; Rigdon, GC; Stocker, JW; Wilson, J | 1 |
Castro, OL; Gladwin, MT; Gordeuk, VR; Steinberg, MH | 1 |
Okpala, IE | 1 |
Aliyu, ZY; Kato, GJ; Tumblin, AR | 1 |
Okpala, I | 1 |
Ataga, KI; Davis, GA; Desimone, PA; Orringer, EP; Stocker, JW; Styles, L; Swerdlow, P; Vichinsky, EP | 1 |
Ataga, KI; Castro, O; De Castro, LM; Kutlar, A; Orringer, EP; Rigdon, GC; Saunthararajah, Y; Smith, WR; Stocker, JW; Swerdlow, P; Vichinsky, E | 1 |
Reviews
7 review(s) available for senicapoc and Anemia, Sickle Cell
Article | Year |
---|---|
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dehydration; Early Termination of Clinical Trials; Erythrocyte Aging; Erythrocytes; Humans; Piracetam; Quality of Life; Randomized Controlled Trials as Topic; Trityl Compounds; Zinc Sulfate | 2018 |
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dehydration; Early Termination of Clinical Trials; Erythrocyte Aging; Erythrocytes; Humans; Piracetam; Randomized Controlled Trials as Topic; Trityl Compounds; Zinc Sulfate | 2016 |
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Animals, Genetically Modified; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hemolysis; Humans; Mice; Trityl Compounds | 2009 |
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Dehydration; Erythrocyte Aging; Erythrocytes; Humans; Randomized Controlled Trials as Topic; Trityl Compounds; Zinc Sulfate | 2010 |
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dehydration; Early Termination of Clinical Trials; Erythrocyte Aging; Erythrocytes; Humans; Piracetam; Randomized Controlled Trials as Topic; Trityl Compounds; Zinc Sulfate | 2012 |
New therapies for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Calcium Channel Blockers; Cell Adhesion; Fatty Acids, Omega-3; Humans; Hydroxyurea; Hypertension, Pulmonary; Iron Overload; Stroke; Trityl Compounds | 2005 |
Investigational agents for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Antihypertensive Agents; Antisickling Agents; Benzaldehydes; Benzoates; Carnitine; Cell Adhesion; Deferasirox; Endothelium, Vascular; Etilefrine; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypertension, Pulmonary; Iron Chelating Agents; Male; Membrane Glycoproteins; Potassium Channels, Calcium-Activated; Priapism; Recombinant Fusion Proteins; Triazoles; Trityl Compounds; Vasoconstrictor Agents | 2006 |
Trials
3 trial(s) available for senicapoc and Anemia, Sickle Cell
Article | Year |
---|---|
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapo
Topics: Acetamides; Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Drug Administration Schedule; Erythrocyte Aging; Female; Hematocrit; Hemolysis; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Male; Middle Aged; Pain; Treatment Outcome; Trityl Compounds; Young Adult | 2011 |
Dose-escalation study of ICA-17043 in patients with sickle cell disease.
Topics: Acetamides; Adult; Anemia, Sickle Cell; Double-Blind Method; Humans; Middle Aged; Potassium Channels, Calcium-Activated; Trityl Compounds | 2006 |
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
Topics: Acetamides; Adolescent; Adult; Anemia, Sickle Cell; Female; Humans; Male; Middle Aged; Potassium Channel Blockers; Time Factors; Treatment Outcome; Trityl Compounds | 2008 |
Other Studies
6 other study(ies) available for senicapoc and Anemia, Sickle Cell
Article | Year |
---|---|
ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Calcium; Calcium Channel Blockers; Clotrimazole; Erythrocytes; Female; Humans; Hypoxia; Male; Mice; Mice, Transgenic; Potassium Channels, Calcium-Activated; Rubidium; Trityl Compounds | 2003 |
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Biological Availability; Clotrimazole; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Male; Mice; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Trityl Compounds | 2008 |
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intermediate-Conductance Calcium-Activated Potassium Channels; Pyrazines; Pyrazoles; Trityl Compounds | 2021 |
Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.
Topics: Acetamides; Adult; Anemia, Sickle Cell; Female; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Trityl Compounds | 2011 |
Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts.
Topics: Acetamides; Anemia, Sickle Cell; Hemoglobin, Sickle; Humans; Pain; Phenotype; Randomized Controlled Trials as Topic; Trityl Compounds | 2011 |
Current therapy of sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Azacitidine; Butyrates; Decitabine; Erythrocyte Transfusion; Humans; Hydroxyurea; Nitric Oxide; Trityl Compounds | 2006 |